Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin Formerly SNS-595
Published in Oncology Business Week, June 22nd, 2008
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced a corporate realignment to focus on the development of the company's lead oncology product candidate, voreloxin (formerly SNS-595). In conjunction with this strategic restructuring, Sunesis expanded the company's late-stage development leadership team and announced a workforce reduction of approximately 60 percent, including the winding down of its research activities. These changes are intended to concentrate the company's financial and human resources on the strongest path to potential near-term value creation for the company's stockholders.
"Based on the promising clinical data achieved to date, we have made a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- 3-1-1 Travel Bag
3-1-1 Travel Bag Donates to St. Jude Children's Research Hospital - Abraxis BioScience, Inc.
ABRAXANE in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer - Acculis Limited
Multi Million Dollar Funding Package for Acculis Limited Microwave Cancer Treatment - Acute Myelogenous Leukemia
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting - Acute Myelogenous Leukemia
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting - Acute Myeloid Leukemia
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595) - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
